Loading
CheckMate 915 asked whether adding a low dose of ipilimumab to nivolumab after melanoma surgery would prevent more recurrences; it did not, and added toxicity, so single-agent PD-1 blockade remains the adjuvant standard.
Nivolumab plus ipilimumab is the most active combination in advanced melanoma, and CheckMate 915 tested whether a lower-toxicity version (ipilimumab 1 mg/kg every six weeks) would improve on nivolumab alone after complete resection of stage IIIB to IV melanoma. It randomised 1844 patients, with recurrence-free survival in the whole population and in PD-L1-low tumours as the dual primary endpoints.
The combination did not improve recurrence-free survival in either population and caused more treatment-related adverse events. Adjuvant nivolumab or pembrolizumab alone remain the standards, and later trials have tested relatlimab (RELATIVITY-098) and neoadjuvant approaches (NADINA) instead.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,844 enrolled.
Median not reached · Median not reached
Source95% CI 22.21 to not reached · 95% CI 19.81 to not reached
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Recurrence-free survival, all randomised participants (registry results)primary | Nivolumab + ipilimumab | - | Median not reached | 0.9 (0.78 to 1.04) | - | link |
| Nivolumab | - | Median not reached | ||||
| Recurrence-free survival, PD-L1 expression below 1% (registry results)primary | Nivolumab + ipilimumab | - | 33.15 months | 0.92 (0.75 to 1.14) | - | link |
| Nivolumab | - | 27.63 months |
Shares Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable, Give immunotherapy in the morning, Randomised trials of stopping immunotherapy after one year versus continuing, Microbiome transplant as a routine immunotherapy adjunct and the tag subtype-trials.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Melanoma, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.
Shares Bristol Myers Squibb and the tag subtype-trials.